Status:
COMPLETED
Study of NGM313 in Obese Participants
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Conditions:
Obese
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants
Eligibility Criteria
Inclusion
- Body mass index (BMI) of 30-43 kg/m2
- Waist circumference \> 40 inches in males or \> 30 inches in females
- Normal ECG readings
Exclusion
- Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
- History of any known Congestive heart failure (CHF)
- History of macrovascular disease
Key Trial Info
Start Date :
September 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 17 2018
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03298464
Start Date
September 11 2017
End Date
July 17 2018
Last Update
March 13 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prosciento
Chula Vista, California, United States, 91911